ImmunoGen (IMGN) Reports Q4 Loss, Tops Revenue Estimates
Published on February 25, 2022
ImmunoGen (IMGN) delivered earnings and revenue surprises of 5.56% and 6.96%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?